Has Amneal Pharmaceuticals (AMRX) Got Too Expensive On Earnings?
Amneal Named BioSpace 2027 Best Place to Work, Ranking No.1 Among Large Employers
Amneal Pharmaceuticals (AMRX) Lifts 2026 Guidance, Is The Upside Already Priced In?
Leerink Partners Maintains Outperform on Amneal Pharmaceuticals, Raises Price Target to $25
JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $25
AMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance Raised
Amneal Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation
Should Raised 2026 Guidance Require Action From Amneal Pharmaceuticals (AMRX) Investors?
Amneal Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
What Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings Call
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call Transcript
Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say
Amneal Pharmaceuticals (NASDAQ:AMRX) Beats Q3 Estimates but Cash-Flow Guidance Weighs on Shares
Amneal (NASDAQ:AMRX) beats expectations in strong Q3 2026, full-year outlook slightly exceeds expectations
Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top Estimates
Amneal Reports Third Quarter 2026 Financial Results
Amneal Pharmaceuticals Q3 2026 Earnings Call Transcript
Amneal (AMRX) Q3 earnings: what to expect
Amneal Pharmaceuticals Raises FY2026 Adj EPS Guidance from $0.96-$1.06 to $1.04-$1.08 vs $1.03 Est; Raises FY2026 Sales Guidance from $3.100B-$3.200B to $3.150B-$3.250B vs $3.159B Est
Amneal Pharmaceuticals Q3 Adj. EPS $0.26 Beats $0.23 Estimate, Sales $862.684M Beat $816.058M Estimate
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.